Welcome to LookChem.com Sign In|Join Free
  • or
4-(imidazo[2,1-b]benzothiazol-2-yl)benzenamine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

950769-48-9

Post Buying Request

950769-48-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

950769-48-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 950769-48-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,0,7,6 and 9 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 950769-48:
(8*9)+(7*5)+(6*0)+(5*7)+(4*6)+(3*9)+(2*4)+(1*8)=209
209 % 10 = 9
So 950769-48-9 is a valid CAS Registry Number.

950769-48-9Relevant academic research and scientific papers

1-Phenyl-: N -(benzothiazol-2-yl)methanimine derivatives as Middle East respiratory syndrome coronavirus inhibitors

Hu, Min-Qi,Li, Heng,Lin, Ying,Tang, Jie,Tang, Wei,Tong, Xian-Kun,Yang, Fan,Yu, Li-Fang,Zhang, Ying,Zuo, Jian-Ping

, p. 43299 - 43311 (2020/12/25)

Middle East respiratory syndrome coronavirus (MERS-CoV) poses a serious threat to human health, and currently there are no effective or specific therapies available to treat it. Herein a series of 1-phenyl-N-(benzothiazol-2-yl)methanimine derivatives with inhibitory activity against MERS-CoV are described. The compound 4f with a 50% inhibition concentration value of 0.09 μM is a promising inhibitor that warrants further evaluation, towards the development of potential anti-MERS-CoV drugs. This journal is

Identification of new aminoacid amides containing the imidazo[2,1-b] benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling

Furlan, Alessandro,Colombo, Francesco,Kover, Andrea,Issaly, Nathalie,Tintori, Cristina,Angeli, Lucilla,Leroux, Vincent,Letard, Sébastien,Amat, Mercedes,Asses, Yasmine,Maigret, Bernard,Dubreuil, Patrice,Botta, Maurizio,Dono, Rosanna,Bosch, Joan,Piccolo, Oreste,Passarella, Daniele,Maina, Flavio

, p. 239 - 254 (2012/03/08)

The Met receptor tyrosine kinase is a promising target in anticancer therapies for its role during tumor evolution and resistance to treatment. It is characterized by an unusual structural plasticity as its active site accepts different inhibitor binding

Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors

-

Page/Page column 14, (2011/04/25)

The present invention concerns novel aminoacids derivatives, in particular some aminoacid amides derivatives, their process of preparation and their use for inhibiting Met-triggered disorders, in particular cancer.

Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors

Christodoulou, Michael S.,Colombo, Francesco,Passarella, Daniele,Ieronimo, Gabriella,Zuco, Valentina,De Cesare, Michelandrea,Zunino, Franco

, p. 1649 - 1657 (2011/04/21)

Since activation of p53 in response to cytotoxic stress may have proapoptotic or protective effects depending on the nature of the injury, inhibitors of p53 may have therapeutic interest as modulators of chemotherapy toxicity or efficacy. In an attempt to

NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY

-

, (2011/04/24)

The present invention concerns novel aminoacids derivatives, in particular some aminoacid amides derivatives, their process of preparation and their use for inhibiting Met-triggered disorders, in particular cancer.

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2- morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

Chao, Qi,Sprankle, Kelly G.,Grotzfeld, Robert M.,Lai, Andiliy G.,Carter, Todd A.,Velasco, Anne Marie,Gunawardane, Ruwanthi N.,Cramer, Merryl D.,Gardner, Michael F.,James, Joyce,Zarrinkar, Patrick P.,Patel, Hitesh K.,Bhagwat, Shripad S.

supporting information; experimental part, p. 7808 - 7816 (2010/09/08)

Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharma

Imidazolothiazole compounds for the treatment of disease

-

Page/Page column 38, (2008/06/13)

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 950769-48-9